Disposition and metabolite kinetics of oral L-carnitine in humans

被引:44
作者
Bain, Marcus A. [1 ]
Milne, Robert W. [1 ]
Evans, Allan M. [1 ]
机构
[1] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst, Adelaide, SA 5000, Australia
关键词
L-carnitine; trimethylamine; trimethylamine-N-oxide; gas chromatography; N-nitrosodimethylamine;
D O I
10.1177/0091270006292851
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The phormacokinetics of L-carnitine and its metabolites were investigated in 7 healthy subjects following the oral administration of 0, 0.5, 1, and 2 g 3 times a day for 7 days. Mean plasma concentrations of L-carnitine across an 8-hour dose interval increased significantly(P < .05)from a baseline of 54.2 +/- 9.3 mu M to 80.5 +/- 12.5 mu M following the 0.5-g dose; there was no further increase at higher doses. There was a significant increase (P < .001) in the renal clearance of L-carnitine indicating saturation of tubular reabsorption. Trimethylamine plasma levels increased proportionately with L-carnitine dose, but there was no change in renal clearance. A significant increase in the plasma concentrations of trimethylamine-N-oxide from baseline was evident only for the 2-g dose of L-carnitine (from 34.5 +/- 2.0 to 149 +/- 145 mu M), and its renal clearance decreased with increasing dose (P < .05). There was no evidence for nonlinearity in the metabolism of trimethylamine to trimethylamine-N-oxide. In conclusion, the pharmacokinetics of oral L-carnitine display nonlinearity above a dose of 0.5 g 3 times a day.
引用
收藏
页码:1163 / 1170
页数:8
相关论文
共 54 条
[1]
DISCLOSURE OF THE METABOLIC RETROVERSION OF TRIMETHYLAMINE N-OXIDE IN HUMANS - A PHARMACOGENETIC APPROACH [J].
ALWAIZ, M ;
AYESH, R ;
MITCHELL, SC ;
IDLE, JR ;
SMITH, RL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (06) :608-612
[2]
THE FISH ODOR SYNDROME - BIOCHEMICAL, FAMILIAL, AND CLINICAL ASPECTS [J].
AYESH, R ;
MITCHELL, SC ;
ZHANG, A ;
SMITH, RL .
BRITISH MEDICAL JOURNAL, 1993, 307 (6905) :655-657
[3]
THE PHARMACOLOGY OF CARNITINE [J].
BAHL, JJ ;
BRESSLER, R .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1987, 27 :257-277
[4]
Quantifying trimethylamine and trimethylamine-N-oxide in human plasma:: interference from endogenous quaternary ammonium compounds [J].
Bain, MA ;
Faull, R ;
Fornasini, G ;
Milne, RW ;
Schumann, R ;
Evans, AM .
ANALYTICAL BIOCHEMISTRY, 2004, 334 (02) :403-405
[5]
BACTERIAL REDUCTION OF TRIMETHYLAMINE OXIDE [J].
BARRETT, EL ;
KWAN, HS .
ANNUAL REVIEW OF MICROBIOLOGY, 1985, 39 :131-149
[6]
PLASMA AND MUSCLE FREE CARNITINE DEFICIENCY DUE TO RENAL FANCONI SYNDROME [J].
BERNARDINI, I ;
RIZZO, WB ;
DALAKAS, M ;
BERNAR, J ;
GAHL, WA .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (04) :1124-1130
[7]
CARNITINE - METABOLISM AND FUNCTIONS [J].
BREMER, J .
PHYSIOLOGICAL REVIEWS, 1983, 63 (04) :1420-1480
[8]
Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria [J].
Cashman, JR ;
Camp, K ;
Fakharzadeh, SS ;
Fennessey, PV ;
Hines, RN ;
Mamer, OA ;
Mitchell, SC ;
Preti, G ;
Schlenk, D ;
Smith, RL ;
Tjoa, SS ;
Williams, DE ;
Yannicelli, S .
CURRENT DRUG METABOLISM, 2003, 4 (02) :151-170
[9]
In vitro and in vivo inhibition of human flavin-containing monooxygenase form 3 (FMO3) in the presence of dietary indoles [J].
Cashman, JR ;
Xiong, Y ;
Lin, J ;
Verhagen, H ;
van Poppel, G ;
van Bladeren, PJ ;
Larsen-Su, S ;
Williams, DE .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (06) :1047-1055
[10]
DURAN M, 1990, J CLIN CHEM CLIN BIO, V28, P359